| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
TD Cowen analyst Joseph Thome maintains Ardelyx (NASDAQ:ARDX) with a Buy and raises the price target from $9 to $10.
Ardelyx (NASDAQ:ARDX) reported quarterly sales of $110.329 million which beat the analyst consensus estimate of $100.878 millio...
IBSRELA patients reported treatment satisfaction in real-world surveyPost-hoc analysis of T3MPO-1 and T3MPO-2 studies demonstra...
Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovati...